

"Women's Health" is also available at www.squarepharma.com.bd

WOMEN'S HEALTH

Vol-4 No.-2 July-September 2011

Editorial Board

Dr. Omar Akramur Rab
MBBS, FCGP, FIAGP

Mohammad Hanif
M. Pharm, MBA

A.H.M.Rashidul Bari
M. Pharm, MBA

Executive Editor

Chowdhury Farhana Faruquee
M. Pharm
e-mail: farhana@squaregroup.com

Editorial Note:


Dear Doctor,

It's our immense pleasure to inform you that we have published our newsletter, "Women's Health". In this issue we are focusing on the **Treatment options for polycystic ovary syndrome**. Your comments and suggestions will enrich our upcoming issues.

Please participate in quiz competition and win prizes.



SQUARE
PHARMACEUTICALS LTD.
BANGLADESH



Treatment options for polycystic ovary syndrome

Introduction

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women. Its prevalence among infertile women is 15%–20%. Several studies have suggested that PCOS is an X-linked dominant condition. Women with PCOS have abnormalities in the metabolism of androgens and estrogen and in the control of androgen production. High serum concentrations of androgenic hormones, such as testosterone, androstenedione, and dehydroepiandrosterone sulfate (DHEAS), may be encountered in these patients. However, individual variation is considerable, and a particular patient might have normal androgen levels. PCOS is also associated with peripheral insulin resistance and hyperinsulinemia, and obesity amplifies the degree of both abnormalities. In addition, insulin resistance in PCOS has been associated with adiponectin, a hormone secreted by adipocytes that regulates lipid metabolism and glucose levels. Both lean and obese women with PCOS have lower adiponectin levels than women without PCOS. A proposed mechanism for anovulation and elevated androgen levels suggests that under the increased stimulatory effect of luteinizing hormone (LH) secreted by the anterior pituitary, stimulation of the ovarian theca cells is increased. In turn, these cells increase the production of androgens (eg, testosterone, androstenedione). Because of a decreased level of follicle-stimulating hormone (FSH) relative to LH, the ovarian granulosa cells cannot aromatize the androgens to estrogens, which leads to decreased estrogen levels and consequent anovulation. Growth hormone and insulin-like growth factor1 may also augment the effect on ovarian function.

Diagnosis of PCOS

The clinical manifestation of PCOS varies from a mild menstrual disorder to severe disturbance of reproductive and metabolic functions. Women with PCOS are predisposed to type 2 diabetes or develop cardiovascular disease. Factors implicated in the low fertility in these patients include anovulation, increased risk of early miscarriage, and late obstetric complications. Clinical manifestations include menstrual disorders and signs of hyperandrogenism. Although not universal and not part of the definition, insulin resistance and obesity are also extremely common.

The 1990 National Institutes of Health (NIH)-sponsored conference for definition required oligo-ovulation, clinical or biochemical hyperandrogenism, and the exclusion of other known disorders, such as late-onset congenital adrenal hyperplasia and Cushing's syndrome (Table 1). The diagnostic criteria of the syndrome were revised by the Rotterdam European Society for Human

Reproduction/American Society of Reproductive Medicine (ASRM)-sponsored PCOS consensus workshop group in 2003, where the following criteria were established: oligo/amenorrhea, clinical and biochemical signs of hyperandrogenism, and sonographically confirmed PCOS. Two of the three criteria are required for diagnosis (after exclusion of other etiologies such as congenital adrenal hyperplasia, androgen-secreting tumors, or Cushing's syndrome). Sonographic features of PCOS include the presence of 12 or more follicles in each ovary measuring 2–9 mm in diameter and/or increased ovarian volume (>10 mL). This is regardless of follicle distribution or ovarian stromal echogenicity. One ovary fulfilling this definition is sufficient to define PCOS. It is recognized that some women with sonographic findings of PCOS may have regular cycles without clinical or biochemical signs of hyperandrogenism. Although this has been a practical working definition, others believe that hyperandrogenism should be an integral part of the definition.

Ovulatory women with PCOS seem to be less insulin resistant than anovulatory women with PCOS; women with PCOS, chronic anovulation, and normal androgen levels are not insulin resistant. These observations limit the usefulness of the Rotterdam criteria, and accordingly an expert panel of the Androgen Excess Society (AES) recommended that PCOS should be considered a disorder of androgen excess and that the NIH diagnostic criteria should be used. The AES also recommended that women with hyperandrogenism, PCOS, and ovulatory cycles should be considered to have a PCOS phenotype; thus, hyperandrogenism and infrequent or irregular ovulation, as well as hyperandrogenism, regular ovulation, and PCOS, fulfill AES criteria for PCOS.

Management of PCOS

Management of women with PCOS depends on the symptoms. These could be ovulatory dysfunction-related infertility, menstrual disorders, or androgen-related symptoms.

WEIGHT REDUCTION

There is some evidence that PCOS-related hyperandrogenism causes central obesity. Obesity is associated with anovulation, miscarriage, or late pregnancy complications. Obesity is observed in 35%–60% of women with PCOS and is related to lack of or delayed response to different treatments.

Weight loss improves the endocrine profile and increases the likelihood of ovulation and pregnancy. Normalization of the menstrual cycles and ovulation could occur with modest weight loss as little as 5% of the initial weight. Weight loss can improve not only circulating androgen and glucose levels but also ovulation and pregnancy rates in

obese women with PCOS; however, weight loss is only recommended for those who are overweight with a BMI > 25–27 kg/m².

Diet

Diets recommended for obese PCOS patients are low in calories with a reduced carbohydrate intake, and any form of these diets can produce the 5%–10% loss. Low-fat diets produce a decrease in hyperinsulinemia, which improves metabolic effects.

Exercise

An increase in physical activity is recommended for PCOS patients, although this often presents limitations.

Bariatric surgery

If spontaneous weight loss cannot be achieved with diet and exercise, bariatric surgery can be offered.

OVULATION INDUCTION

In PCOS, anovulation relates to low FSH concentrations and the arrest of antral follicle growth in the final stages of maturation. Excess LH, androgens, and insulin may individually or collectively play a direct or indirect role in this process, augmenting steroidogenesis but arresting follicular growth. For many women, anovulatory infertility is the presenting complaint. Medications and other options available for the induction of ovulation are reviewed in the following sections.

Clomiphene citrate (CC)

CC constitutes one of the first-line treatments for ovulation induction in these patients, as it is economical, is straightforward, has few adverse effects, and requires little monitoring. CC is an estrogen receptor antagonist that interferes with negative feedback of the estrogen-signaling pathway, resulting in increased availability of FSH. Increased FSH leads to follicular growth, followed by an LH surge and ovulation. CC is indicated in patients with PCOS and anovulation with normal FSH levels, but it has certain limitations in patients with a BMI >30 and advanced age.

Doses of 50–150 mg are administered for 5 days, starting on days 3 or 5 of a progestin-induced or spontaneous cycle. CC produces ovulation in 75%–80% of PCOS patients, although when the gestation rate is assessed, it nears 22% per ovulation cycle. These differences in results are attributed to the antiestrogenic effects of CC, mainly on the endometrium and the cervical mucus. The live birth rate following 6 months of clomiphene ranged from 20% to 40%. Furthermore, the majority of pregnancies occurred within the first six ovulatory cycles following the initiation of treatment. Multiple pregnancy rates are under 10%, and hyperstimulation syndrome is rare. Tamoxifen is another oral ovulatory agent that is similar to CC in its mechanism of action, but it lacks its antiestrogenic effect on the cervix and endometrium. It can be used as an alternative to CC in case of CC resistance or failure.

Table 1. Diagnostic criteria

Organization/group	Year	Criteria
National Institutes of Health	1990	Both hyperandrogenism and chronic anovulation.
Rotterdam European Society for Human Reproduction/American Society of Reproductive Medicine-sponsored PCOS consensus workshop group	2003	Two of the following conditions: hyperandrogenism, chronic anovulation, polycystic ovary.
Androgen Excess Society	2006	Hyperandrogenism and ovarian dysfunction (including infrequent or irregular ovulation or anovulation) and/or polycystic ovary

Metformin

Metformin is approved to manage type 2 diabetes mellitus. The use of metformin is associated with increased menstrual cyclicality, improved ovulation, and a reduction in circulating androgen levels. Metabolic benefits are enhanced in the presence of weight loss, and weight loss itself may be enhanced in the presence of metformin. Metformin likely plays its role in improving ovulation induction in women with PCOS through a variety of actions, including reducing insulin levels and altering the effect of insulin on ovarian androgen biosynthesis, theca cell proliferation, and endometrial growth.

Several dose regimens have been proposed. In order to increase patient tolerance, metformin is started at 500 mg daily with food. After 1 week, the dose is increased to 1000 mg for another week and then to 1500 mg daily. The target dose is 1500–2550 mg/day (500 or 850 mg three times daily). Clinical response is usually seen at the dose of 1000 mg daily. It appears that some PCOS patients who do not respond to metformin at a dose of 1500 mg daily will respond favorably to 2000 mg daily. The most common side effects of metformin are nausea and diarrhea. Lactic acidosis has been described mainly in patients with renal impairment, congestive heart failure, and sepsis. Traditionally, oral hypoglycemic agents have been regarded as teratogenic, and their use is contraindicated in pregnancy. However, an increasing amount of data supports their safety when used throughout the pregnancy.

To define the exact role of metformin in ovulation induction, it is crucial to distinguish two different indications. In naive PCOS, metformin, as compared with placebo, has been shown to improve ovulation rates, but metformin did not exert significant advantage over CC with respect to cumulative ovulation, pregnancy, or live birth rates. The combined approach of metformin plus CC is not better than CC or metformin monotherapy in naive PCOS. In CC-resistant patients, metformin has no benefit over

placebo in ovulation, pregnancy, and live birth rates as a single agent, but the combination of metformin and CC significantly improved ovulation and pregnancy rates when compared with CC alone. However, combined therapy did not improve the odds of live birth. Metformin pretreatment improves the efficacy of CC in PCOS patients with CC resistance.

Rosiglitazone (8 mg/day), has been shown to enhance both spontaneous and clomiphene-induced ovulation in women with PCOS with a mean BMI of 35.5-38.5 kg/m². Pioglitazone appears to be effective as well; however, the study is still limited. Although both rosiglitazone and pioglitazone have little short-term risk, fetal safety has not been established (pregnancy category C of the US FDA guidelines). If used, they should be discontinued as soon as pregnancy has been established. There is no evidence that metformin improves live birth rates whether it is used alone or in combination with clomiphene, or when compared with clomiphene. Therefore, the use of metformin in improving reproductive outcomes in women with PCOS appears to be limited.

Aromatase inhibitors

Selective aromatase inhibitors such as anastrozole and letrozole are promising new ovulation-inducing agents. They are reversible and highly potent. Unlike CC, which has a half-life of 5-7 days, the mean half-life of anastrozole and letrozole is ~45 h only. To date, letrozole has been studied much more extensively than anastrozole. Letrozole inhibits estrogen production in the hypothalamus-pituitary axis, which implies an increase in gonadotropin-releasing hormone (GnRH) and FSH. It is believed that there exists a relative decrease in aromatase in women with PCOS, which reduces the production of follicles responsible for efficacious ovulation. To use this relative deficit, aromatase inhibitors were considered in order to provoke ovulation, because their selective action of blocking the peripheral passage of androgens to estrogens reduces the quantity of estrogens, thereby producing positive feedback in the pituitary, increasing FSH, and optimizing ovulation. The advantage of letrozole is that it avoids peripheral antiestrogenic effects on the endometrium while stimulating monofollicular growth. Letrozole at 2.5-5 mg is administered for 5 days and may be accompanied by FSH (at the normal doses for PCOS patients) and human chorionic gonadotropin (hCG; 10,000 IU) when the follicle diameter reaches 18 mm in order to program the ovulation. Although Novartis Pharmaceuticals has warned against the use of letrozole for ovulation induction (owing to possible teratogenicity), a comparison with clomiphene did not demonstrate increased rates of major or minor malformations.

Glucocorticoids

Glucocorticoids such as prednisone and dexamethasone have been used to induce ovulation. Elnashar et al demonstrated that induction of ovulation by adding dexamethasone (high dose, short course) to CC in CC-

resistant PCOS with normal DHEAS is associated with no adverse antiestrogenic effect on the endometrium and higher ovulation and pregnancy rates in a significant number of patients.

In PCOS patients with high adrenal androgen, low-dose dexamethasone (0.25-0.5 mg) at bedtime can be used. In a study of 230 women with PCOS who failed to ovulate with 200 mg of CC for 5 days, addition of 2 mg of dexamethasone from days 5-14 is associated with a higher ovulation rate and cumulative pregnancy rate. Enthusiasm for their use is dampened, however, by their potential adverse effects on insulin sensitivity; therefore, prolonged use should be discouraged.

Gonadotropins

The second possible line of therapy after resistance to CC has been demonstrated in women with PCOS is exogenous gonadotropins. The mechanism of action of gonadotropins is to induce ovulation, maintain and provoke optimum follicle growth via the controlled administration of FSH, and achieve a follicle capable of being fertilized. Unlike CC, gonadotropin does not exert a peripheral antiestrogenic effect. The main drawback of gonadotropins is that they provoke multiple follicle development, thereby increasing the risk of ovarian hyperstimulation syndrome (OHSS) and multiple pregnancies. Treatment with FSH is expensive, is time consuming, and requires expertise and stringent monitoring.

Several treatment protocols have been advocated, such as step-up, low-dose step-up, and step-down regimens. The ASRM recommends low-dose gonadotropin protocols. A step-up dose-finding approach favoring unifollicular development is recommended. The step-up regimen starts with a minimum dose (37.5-50 IU/day), which increases according to the lack of follicle response. Control is made by ultrasound, and the regimen is modified after 1 week of no follicle growth with a 50% increase each time as required. HCG is used as a surrogate for the LH surge, leading to maturation of the oocyte, rupture of the follicle, and formation of the corpus luteum. The step-down regimen starts with the maximum recommended dose, which is reduced as a follicle response is achieved. The dose is reduced by 50% each time the regimen is changed. Recent studies have demonstrated greater safety for patients using the step-up regimen.

In 2006, the ASRM advocated caution and strict control when blood estradiol levels exceed 2500 pg/mL during induction. Current recommendations suggest withholding hCG administration in the presence of more than two follicles >16 mm or more than one follicle >16 mm and two additional follicles >14 mm, or if serum estradiol levels are between 1000 and 2500 pg/mL, particularly in women < 38 years old without any other infertility factors. Overall, low-dose regimens resulted in a monofollicular ovulation rate of ~70%, a pregnancy rate of 20% per cycle, and a multiple live birth rate of 5.7% while maintaining a low

incidence of multiple pregnancies (<6%) and OHSS (<1%). A maximum of six cycles with gonadotropins is recommended because no response with six cycles signifies resistance.

Laparoscopic ovarian diathermy

In clomiphene-resistant PCOS women who are unable to comply with the close monitoring necessary for gonadotropin administration, bilateral laparoscopic ovarian surgery with monopolar electrocautery (multiple controlled perforation of the ovary) or laser is an acceptable alternative; both modalities confer similar results. Laparoscopic ovarian diathermy (LOD) is associated with lower multiple gestation rates than gonadotropins. In a Cochrane Database Systematic Review article, there was no evidence of a difference in live birth rate and miscarriage rate in women with clomiphene-resistant PCOS undergoing LOD versus gonadotropin treatment. It appears to be more effective in patients with high LH, and significant reductions in LH and androgens. LOD restores menstrual regularity in 63%-85%, and the beneficial effects on reproductive outcomes seem to last for several years in many women. Treatment with metformin is equally efficacious in correcting the clinical, endocrine, and metabolic abnormalities associated with PCOS.

In vitro fertilization techniques

The last possibility for achieving a full-term pregnancy in women with PCOS is to use in vitro fertilization (IVF) techniques. Patients with PCOS are characterized by anovulatory cycles that conceptually are not an indication for IVF techniques. These techniques are used as a last resort when treatments with CC, gonadotropins, and letrozole have failed. IVF is the first choice in cases of concomitant diseases both in women (severe endometriosis, tubal obstruction, etc) and men (azoospermia, male factor) that reduce the effectiveness of other techniques. Because of the increased risk of multiple gestations (up to 10%) with gonadotropin induction in anovulatory women with PCOS, IVF is a reasonable alternative for women seeking pregnancy.

Several stimulation protocols have been published for the treatment of patients with PCOS undergoing IVF, including combinations or isolated use of clomiphene, human menopausal gonadotropins, recombinant FSH, GnRH agonists, and GnRH antagonists. According to the 2008 ASRM consensus conference, the most commonly employed protocol is a long FSH desensitization protocol in which an agonist is started in the early, mid, or late luteal phase in the preceding cycle or in the follicular phase until hCG administration. Stimulation with gonadotropins is started when pituitary and ovarian suppression has been achieved. A meta-analysis published in 2006, which studied the results of conventional IVF techniques in women with PCOS, revealed more cycle cancellation and that the duration of stimulation cycles was significantly longer in women with PCOS. There is evidence that the use of metformin

improves viable pregnancy rates and reduces the incidence of OHSS. The success of IVF techniques is similar to that of patients without PCOS, which implies that PCOS does not intervene in embryo implantation.

TREATMENT OF MENSTRUAL DYSFUNCTION

Chronic anovulation is associated with an increased risk of endometrial hyperplasia and carcinoma. Thus, it is prudent to consider endometrial biopsy in patients with PCOS who have not had menstrual bleeding for a year or longer. Some investigators have advocated the use of ultrasonography to determine endometrial thickness in deciding whether to do a biopsy of the endometrium. Endometrial proliferation can be inhibited by administering either cyclic progestin or oral contraceptives with a combination of estrogen and progestin. The latter approach, which also reduces ovarian androgen production, may be particularly beneficial in this setting.

TREATMENT OF ANDROGEN RELATED SYMPTOMS

The over-riding androgenic symptoms that the individual presents will vary from patient to patient; for some it is mainly hirsutism, but for others it is acne and/or alopecia. Many have both hirsutism and acne, and a few complain of significant acne, hirsutism, and alopecia.

Hirsutism

Overall, 70%-80% of women with excess androgen demonstrate hirsutism, usually defined as a Ferriman-Gallwey score of at least 8, although this prevalence is less in certain ethnic groups, such as East Asians, who may have fewer hair follicles endowed per unit area of skin. Androgens increase the growth rate of hair and transform vellus hair to terminal hair. Reduction of androgens reduces new hair growth and slows the growth of terminal hair that is already present. The effects of hormonal therapy require more than 6 months to be maximal.

Oral contraceptive pills

In women who have no desire to conceive, they can be treated with oral contraceptive pills (OCPs). OCPs reduce hyperandrogenism by promoting direct negative feedback on LH secretion, which results in decreased ovarian synthesis of androgens. Further, they increase liver production of sex hormone-binding globulin and subsequently decrease circulating free androgen. The choice of oral contraceptive is important, because most progestins also possess variable androgenic effects. Available low-dose OCPs (defined as <50 µg) contain ethinyl estradiol in doses ranging from 15 µg to 35 µg. An important consideration for the progestin component is the degree of androgenicity of the progestin. Newer OCPs contain fewer androgenic progestins (such as norethindrone, desogestrel, and norgestimate), and two progestins (cyproterone acetate [CPA], which is used in low doses in OCPs, and drospirenone) function as androgen receptor antagonists, CPA being more potent in its effect. CPA may also inhibit 5- α -reductase activity, decreasing the availability of the more potent androgen,

dihydrotestosterone. A third antiandrogenic progestin, dienogest, has recently become available in Europe and is combined with estradiol as an OCP. One of the newest OCPs that might be more effective in reducing the growth of new terminal hair and acne formation is a formula that contains a combination of nonandrogenic progestin, drospirenone, and ethinyl estradiol; thus, it is potentially ideal for the treatment of women with PCOS. Drospirenone is a spironolactone analog with mineralocorticoid activity; as a result, it has some diuretic property. However, it should not be prescribed to those predisposed to hyperkalemia. Treatment must be given for at least 6–9 months before improvement in hirsutism can be seen.

Estrogen–progestin combination therapy (with the use of a combination OCP) remains the predominant treatment for hirsutism and acne in PCOS. Controversy persists regarding the use of OCPs as first-line therapy in women with PCOS. These agents clearly improve hirsutism and acne and protect against unopposed estrogenic stimulation of the endometrium, but their potential adverse effects on insulin resistance, glucose tolerance, vascular reactivity, and coagulability are a concern, particularly now that insulin-lowering agents are available.

Antiandrogens

Antiandrogens such as spironolactone, CPA, or flutamide act by competitive inhibition of androgen-binding receptors or by decreasing androgen production.

Spironolactone, which is an aldosterone antagonist, is a dose-dependent competitive inhibitor of the androgen receptor and can also inhibit 5- α -reductase activity. Spironolactone possesses moderate antiandrogenic effects when administered in large doses (100–200 mg daily). It has demonstrable effects on hirsutism over and above those induced by OCPs. Although generally well tolerated, it occasionally causes fatigue, postural hypotension, and dizziness, and when administered alone in high doses, it may cause menstrual irregularity. The risk of feminizing a male fetus, if pregnancy occurs, precludes its use as monotherapy in sexually active women with PCOS. Spironolactone and oral contraceptives appear to be synergistic. Thus, it is often used with OCPs.

CPA is a progestational antiandrogen. CPA competitively inhibits the binding of testosterone and its more potent conversion product 5- α -dihydrotestosterone to the androgen receptor. Used in high doses (50–100 mg) and in a reverse sequential regimen (for the first 10 days of cycle), in combination with ethinyl estradiol 20–50 μ g (to ensure regular menses), it was shown to be more effective than finasteride, a 5- α -reductase inhibitor. CPA is generally well tolerated, although it may cause headaches, nausea, weight gain, breast tenderness, loss of libido, and, rarely, hepatotoxicity effects. As with spironolactone, there is a risk of feminizing a male fetus. A combination of ethinyl estradiol and CPA is very effective in treating hirsutism and acne. Apart from its antiandrogenic effect,

CPA has a marked progestational property preventing ovulation. Loss of hair, which frequently accompanies seborrhea, also improves. Frequent monitoring of liver and renal function is necessary during therapy with antiandrogens. Similar to that with OCP, improvement of hirsutism is expected to be noticeable after 6 months of treatment. Although there is a considerable variation among individuals, the maximum effect is usually seen after 9–12 months of antiandrogen treatment.

Flutamide is a nonsteroidal, selective antiandrogen without progestogenic effect. It is very effective in treating hirsutism. In a dose of 500 mg daily, it was found to be similarly effective as spironolactone 100 mg in women with idiopathic hirsutism, and, in a recent study, the minimal effective dose was found to be 125 mg daily. Its major concern is serious hepatotoxicity, although doses up to 375 mg have been used without any significant hepatotoxicity. However, it is rarely used alone due to its high cost and the risk of hepatocellular toxicity. Recent studies have indicated that a combination of flutamide 62.5 mg daily with metformin 850 mg daily is more effective in improving symptoms of PCOS than OCP alone.

Finasteride is a type 2 (5- α -reductase) activity inhibitor that inhibits the production of dihydrotestosterone. Enhanced 5- α -reductase activity in hirsutism probably involves both type 1 and type 2 enzymes, so it is unlikely to be an optimal treatment. Hirsutism scores were lower in studies of finasteride. Finasteride has also been used in combination with a CPA-containing OCP, and the addition of finasteride 5 mg to the OCP was shown to be better than the OCP alone. Although finasteride has a low side effect profile, its feminizing effects on a male fetus preclude its use in most patients.

Glucocorticoids

Some women with PCOS have elevated adrenal androgen levels, although their contribution to ovulatory dysfunction appears modest. Glucocorticoids suppress adrenal androgen secretion and have been used in patients with adrenal hyperandrogenism. Their use is most legitimate in patients with classic congenital adrenal hyperplasia, where they can help prevent and manage hirsutism and allow ovulatory cycles. In nonclassic congenital adrenal hyperplasia and functional adrenal androgen excess (a minority of PCOS patients), their role is more limited. Suppression of adrenal androgens results in a minor improvement of hirsutism, although prolonged remission after therapy withdrawal can be obtained. A trial of CPA versus hydrocortisone in patients with late-onset congenital adrenal hyperplasia showed a greater decrease in hirsutism scores with 1 year of CPA compared with hydrocortisone (54% vs 26%). These results occurred despite a greater reduction of androgens with glucocorticoids, highlighting the importance of peripheral receptivity to androgens. Overdosing can occur, leading to adrenal atrophy, weight gain, and decreased bone mineral density. Glucocorticoid (5–7.5 mg

of prednisone once or twice daily) has been shown to improve hirsutism in women with congenital adrenal hyperplasia. However, its effect on hirsutism due to other causes is unclear. Unless a woman with PCOS has marked adrenal androgen excess, prolonged use of glucocorticoids is not advised.

Gonadotropin-releasing hormone agonist

Gonadotropin-releasing hormone agonist (GnRHa) is effective even in women with severe insulin resistance who are unresponsive to OCP. GnRHa suppresses pituitary hormones, decreases androgen and estradiol secretion, and improves severe forms of hirsutism. To avoid problems associated with estrogen deficiency, 'add-back' therapy with estrogen-progesterone or low-dose OCP is advisable. However, this method of treatment is expensive, limiting its use to severe forms of ovarian hyperandrogenism with hyperinsulinemia.

Insulin-lowering agents

Both metformin and thiazolidinediones may lower ovarian androgen secretion, mainly through their insulin-lowering effects. In a Cochrane Database Systematic Review article, limited data on small numbers of patients have shown no evidence of a difference in effect between metformin and OCPs on hirsutism and acne. Some effects of rosiglitazone on hirsutism were shown by Yilmaz et al and troglitazone (no longer available) improved hirsutism in women with PCOS.

Direct hair removal

Electrolysis has been used for many years to remove unwanted hair.

Topical treatment

Eflornithine hydrochloride, an inhibitor of the enzyme ornithine decarboxylase in human skin, has been approved for topical use in treating facial hirsutism, taking 6–8 weeks for its effect to be apparent. It can be combined with laser treatment.

Combination therapy

In the Endocrine Society Practice Guidelines discussing the evaluation and treatment of hirsutism in premenopausal women, it was recommended that OCPs or direct hair removal be used initially. Then, if at least 6 months of OCP therapy has not significantly decreased the rate of hair growth, antiandrogens may be added.

Acne

Both OCPs and antiandrogens have been used successfully in the treatment of acne. Within 3–6 months of OCP treatment, inflammatory acne counts are reduced by 30%–60%, with improvement in 50%–90% of patients. OCPs are especially useful in patients with deep-seated nodules and helpful in patients relapsing on isotretinoin.

Alopecia

There are no extensive trials for alopecia, but OCPs and androgen blockers are usually administered. In limited studies, CPA has had some effect, as has finasteride.

Ref: *Treatment options for polycystic ovary syndrome. Ahmed Badawy, Abubaker Elnashar. International Journal of Women's Health 2011;3 25–35.*

Congratulations! Congratulations! Congratulations!

The Winners of **WOMEN'S HEALTH** *Quiz Competition* (Vol-4, No.-1, January-March 2011)

<p>Dr. Fatema Siddiqua DGO, FCPS, Islami Bank Hospital, Rajshahi</p>	<p>Dr. Dil Afroza Bashar MBBS, MCPS, FCPS (Obs & Gynae) "Dil Mahal", Newbabupara, Saidpur, Nilphamary</p>
<p>Dr. Naznin Siddique MBBS, FCPS-P II (Obs & Gynae) Al Sefa General hospital, Bhairab</p>	

Congratulations! Congratulations!

Geston™

Allylestrenol 5 mg Tablet

Healthy Pregnancy, Healthy Baby



- ✔ Protects & maintains pregnancy
- ✔ Gives rapid placentotrophic activity
- ✔ Effective in Intra Uterine Growth Retardation
- ✔ Prevents threatened premature delivery

Menoral®

Norethisterone 5 mg Tablet

For better menstrual health

- ➔ Potent & biologically active progestogen
- ➔ Offers better therapeutic effects in various menstrual complications
- ➔ The first choice progestogen with maximum compliance
- ➔ Safer than other progestins in long term use
- ➔ Launched from dedicated hormone & steroid product manufacturing facility

Comet®

Metformin HCl

Available as

500 mg, 750 mg Tablet
850 mg, 1 gm Tablet
XR 500 mg, XR 1 gm Tablet

First line therapy for type 2 diabetes

fights against **breast cancer** as well




Lerozol®

Letrozole 2.5 mg Tablet

A new approach for ovulation induction

- ➔ Anovulation
- ➔ PCOS (Polycystic Ovarian Syndrome)
- ➔ Pituitary disorders
- ➔ Irregular menstruation



SQUARE
PHARMACEUTICALS LTD.
BANGLADESH



www.squarepharma.com.bd

